# Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

> **NCT04156087** · PHASE2 · COMPLETED · sponsor: **Baki Topal** · enrollment: 12 (actual)

## Conditions studied

- Pancreatic Cancer Non-resectable

## Interventions

- **DRUG:** Durvalumab 50 MG/ML
- **DRUG:** Tremelimumab
- **DRUG:** Gemcitabine
- **PROCEDURE:** Minimally Invasive Surgical Microwave Ablation (MIS-MWA)

## Key facts

- **NCT ID:** NCT04156087
- **Lead sponsor:** Baki Topal
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-05-09
- **Primary completion:** 2024-01-29
- **Final completion:** 2024-01-29
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04156087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04156087, "Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04156087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*